利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.012 秒)

    METHOD FOR THE GENERATION OF T CELL HYBRIDOMA FOR CLONING AND ANALYSIS OF RECEPTORS USING ENGINEERED MEASLES VIRUS FUSOGENIC GLYCOPROTEINS
    1.
    发明公开
    METHOD FOR THE GENERATION OF T CELL HYBRIDOMA FOR CLONING AND ANALYSIS OF RECEPTORS USING ENGINEERED MEASLES VIRUS FUSOGENIC GLYCOPROTEINS 审中-公开
    产生T细胞杂交瘤克隆的方法和使用工程化的病毒的融合蛋白

    公开(公告)号：EP3284819A1

    公开(公告)日：2018-02-21

    申请号：EP16184334.7

    申请日：2016-08-16

    申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC) ,  Humboldt Universität zu Berlin

    发明人： Bunse, Mario ,  Edes, Inan ,  Uckert, Wolfgang

    IPC分类号： C12N5/0783 ,  C07K14/12

    CPC分类号： C12N5/163 ,  C07K14/12 ,  C07K2319/33 ,  C12N2510/04

    摘要： The invention relates to the field of immunology and immunotherapy, in particular, to adoptive T cell therapy of cancer utilizing T cell receptor (TCR)-engineered T cells. The invention provides novel methods and tools for identification and cloning of TCR, which are also applicable for identification of other receptors such as B cell receptors or antibodies. The invention provides immortalized cell lines able to induce subset specific (e.g. CD4 + or CD8 + specific) hybridization during co-culture, e.g., with primary lymphocytes of mice or men. The immortalized cells are engineered to express two mutated glycoproteins derived from the paramyxovirus family, namely hemagglutinin (H) and fusion (F) or a derivative thereof. H is a chimeric protein not able to bind to its natural ligands, fused to a targeting ligand capable of specifically binding to a specific cell surface antigen such as a lymphocytic subset-marking ligand (e.g. CD4 or CD8); fusion (F) mediates the fusion of cellular membranes of the immortalized cell line and cells, e.g., primary lymphocytes, H has bound to. The methods of the invention comprise preparing a hybridoma cell expressing a receptor, comprising steps of co-culturing a cell expressing a specific cell surface antigen and said receptor with the specific immortalized cells of the invention. The invention also relates to the hybridoma cells obtainable by said method.

    摘要翻译： 本发明涉及免疫学和免疫治疗领域，特别涉及利用T细胞受体（TCR） - 工程化T细胞的癌症的过继性T细胞治疗。 本发明提供了鉴定和克隆TCR的新方法和工具，其也可用于鉴定其他受体如B细胞受体或抗体。 本发明提供了永生化细胞系，其能够在共培养期间（例如与小鼠或男性的原代淋巴细胞）诱导子集特异性（例如CD4 +或CD8 +特异性）杂交。 工程化永生化细胞以表达衍生自副粘病毒科的两种突变糖蛋白，即血凝素（H）和融合蛋白（F）或其衍生物。 H是不能与其天然配体结合的嵌合蛋白，与能够特异性结合特定细胞表面抗原如淋巴细胞亚群标记配体（例如CD4或CD8）的靶向配体融合; 融合体（F）介导永生化细胞系和细胞（例如H已结合的初级淋巴细胞）的细胞膜融合。 本发明的方法包括制备表达受体的杂交瘤细胞，其包括将表达特定细胞表面抗原的细胞和所述受体共同培养于本发明的特定永生化细胞的步骤。 本发明还涉及通过所述方法可获得的杂交瘤细胞。

    Multiple target T cell receptor
    4.
    发明公开
    Multiple target T cell receptor 有权
    Mehrfachziel-T-Zellen-Rezeptor

    公开(公告)号：EP2258720A1

    公开(公告)日：2010-12-08

    申请号：EP10163251.1

    申请日：2010-05-19

    申请人： Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;

    发明人： Kieback, Elisa ,  Charo, Jehad ,  Blankenstein, Thomas ,  Uckert, Wolfgang ,  Perez, Cynthia

    IPC分类号： C07K14/705 ,  C12N15/62 ,  A61K38/17 ,  A61P35/00

    CPC分类号： C07K14/7051 ,  A61K38/00 ,  C07K2319/33

    摘要： The present invention is directed to a functional T cell receptor (TCR) fusion protein (TFP) recognizing and binding to at least one MHC-presented epitope, and containing at least one amino acid sequence recognizing and binding an antigen. The present invention is further directed to an isolated nucleic acid molecule encoding the same, a T cell expressing said TFP, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.

    摘要翻译： 本发明涉及识别和结合至少一个MHC呈递的表位并且含有至少一个识别和结合抗原的氨基酸序列的功能性T细胞受体（TCR）融合蛋白（TFP）。 本发明还涉及编码该分离的核酸分子，表达所述TFP的T细胞和用于治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病的药物组合物。

    T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells
    5.
    发明公开
    T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells 审中-公开
    基于T细胞的包装细胞，用于通过富集CD3表达细胞生产反转录病毒的

    公开(公告)号：EP1739180A1

    公开(公告)日：2007-01-03

    申请号：EP05013833.8

    申请日：2005-06-27

    申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC)

    发明人： Uckert, Wolfgang ,  Blankenstein, Thomas

    IPC分类号： C12N15/867 ,  C12N5/06 ,  C12N5/10

    CPC分类号： C12N7/00 ,  A01K2217/05 ,  C07K14/7051 ,  C12N5/0636 ,  C12N15/86 ,  C12N2740/13043 ,  C12N2740/13045 ,  C12N2740/13052 ,  C12N2810/6054

    摘要： The present invention relates to retroviral vector systems, in particular the development of packaging or helper cell lines that are based on T cells and that are suitable for producing T cell receptor retroviruses. Thereby, the present invention relates to T cell line specific retroviral expression vectors, and mammalian T cell line-based helper cell lines. The invention further relates to methods for expressing transgenes and to T cell line specific retroviral vector systems, including biochemical kits, that utilize and/or comprise the T cell line specific retroviral expression vectors and/or mammalian T cell line-based helper cell lines.

    摘要翻译： 本发明涉及反转录病毒载体系统，特别是包装或辅助细胞系的开发并基于T细胞和确实适合于生产的T细胞受体的逆转录病毒。 由此，本发明涉及T细胞系特异性逆转录病毒表达载体，和哺乳动物T细胞系为基础的辅助细胞系。 本发明还涉及到用于表达的转基因和T细胞系特异性的逆转录病毒载体系统的方法，包括生化试剂盒，并使用和/或包含T细胞系特异性逆转录病毒表达载体和/或哺乳动物T细胞系为基础的辅助细胞系。